TDC
ICPT

Thompson Davis & Co’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Thompson Davis & Co’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-390
Closed -$61K – 1284
2014
Q4 		$61K Buy
+390
New +$72K 0.07% 247

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Thompson Davis & Co's ICPT Position: Q1 2015 in Review

Thompson Davis & Co sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2015, closing a stake of 390 shares — an estimated $61K sold.

Thompson Davis & Co first reported a position in ICPT in Q4 2014 and held it in 1 quarter. The position peaked at $61K in Q4 2014. 200 funds tracked by Wall St. Rank hold ICPT as of Q1 2015.

  • Thompson Davis & Co reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Thompson Davis & Co sold 390 Intercept Pharmaceuticals, Inc. shares in Q1 2015, an estimated $61K.
  • Thompson Davis & Co first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Intercept Pharmaceuticals, Inc. position peaked at $61K in Q4 2014.
  • 200 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2015, filed 28 Apr 2015.